Skip to main content
AGMB logo

AgomAb Therapeutics NV

AGMBNASDAQHealthcareBiotechnology

$8.28Today:- (-)

As of Oct 16, 2026 close

Market cap
$339.56M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$7.97$17.82
Volume (live)
-
Avg. volume (3M)
153.49K

AgomAb Therapeutics NV (AGMB) Cash Flow Statement

In fiscal 2025 (fiscal year ended Mar 31, 2026), AgomAb Therapeutics NV used EUR 51.74M of cash in operating activities and spent EUR 4.00K on capital expenditures. That left free cash flow of −EUR 51.74M.

AgomAb Therapeutics NV Cash Flow Statement Analysis

Values in millions EUR

Income StatementBalance SheetCash FlowRatios
Scroll to see more
Cash flow statement showing operating, investing, and financing activities for AgomAb Therapeutics NV (AGMB) - Annual data in millions EUR
BreakdownFY 2025FY 2025FY 2024FY 2023FY 2022FY 2019FY 2018
Period endingMar 2026Dec 2025Dec 2024Dec 2023Dec 2022Dec 2019Dec 2018
Operating Activities
Net Income-62.55-62.55-46.27-11.39-8.14--
Depreciation & Amortization0.220.220.310.100.02--
Deferred Income Tax0.00-0.00-0.62-2.66--
Stock Based Compensation5.365.361.072.162.21--
Change in Working Capital0.410.41-1.284.121.41--
Change in Accounts Payable0.002.36-0.233.692.95--
Change in Other Working Capital0.41-1.55-1.141.240.06--
Other Operating Activities4.83-1.55-1.14-19.800.06--
Net Cash from Operating Activities-51.74-51.74-46.83-24.59-18.97--
Investing Activities
Capital Expenditures0.000.00-0.68----
Acquisitions-3.00-3.00---4.59--
Purchases of Investments-30.00-30.00-40.00-40.00--
Sales/Maturities of Investments0.00--40.00---
Net Cash from Investing Activities-33.00-33.00-0.6840.00-44.59--
Financing Activities
Debt Repayment-0.34-0.34-0.16-0.10-0.72--
Common Stock Issued0.00-97.0679.8738.39--
Other Financing Activities0.00-0.34-0.13-0.45-0.04--
Net Cash from Financing Activities-0.34-0.3496.7679.3237.63--
Summary
Effect of Forex Changes on Cash0.050.05-0.20----
Net Change in Cash-85.04-85.0849.2694.73-25.92--
Cash at Beginning of Period171.46171.46122.4027.6753.59--
Cash at End of Period86.4286.42171.46122.4027.67--
Free Cash Flow-51.75-51.75-47.50-24.59-18.97--
Supplemental Disclosures
Interest Paid--0.010.020.04--
Income Taxes Paid--0.000.000.00--

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About AgomAb Therapeutics NV Cash Flow

What is AgomAb Therapeutics NV's free cash flow?

AgomAb Therapeutics NV had negative free cash flow of EUR 51.74M in fiscal 2025 (fiscal year ended Mar 31, 2026), operating cash flow of −EUR 51.74M minus EUR 4.00K of capital expenditures.

How much does AgomAb Therapeutics NV spend on capital expenditures?

AgomAb Therapeutics NV spent EUR 4.00K on capital expenditures in fiscal 2025, compared with EUR 675.00K a year earlier.

Does AgomAb Therapeutics NV pay dividends or buy back shares?

AgomAb Therapeutics NV's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition